

No.	M/O	Label	Type	Size	Name	Description
1	M		C	7	SÚKL code	Code of the medicinal product ("MP") allocated by SÚKL to the presentation of the MP as part of the marketing authorisation (MA) of the MP, or allocated to a non-authorised MP included in a specific therapeutic programme ("STP"), or allocated to food for special medical purposes ("FSMP")
2	M		C	70	Name of medicinal product	Name of the MP or FSMP
3	M		C	30	Medicinal product specification	MP's name supplement, which clearly defines the presentation of the MP and which consists of an integration of its route of administration, pharmaceutical form, pack size and strength. This item of the List is further detailed under items CESTA, FORMA, BALENI and SILA
4	M		C	7	Route of administration	Route of administration
5	M		C	19	Pharmaceutical form	Pharmaceutical form
6	M		C	22	Pack	Pack size
7	M		C	15	Strength	The strength of the MP, i.e. the contents of active substances expressed qualitatively pro rata to a unit of dose, volume or weight, depending on the pharmaceutical form.
8	M		C	3	Packaging	The immediate packaging of the MP, i.e. form of packaging that is in immediate contact with the MP.
9	O		C	4	MA holder	Marketing authorisation holder's abbreviation. A common implemental index is available for the DRZ and ZEM DRZ fields.
10	O		C	3	Holder's country	An abbreviation of the country of the marketing authorisation holder's registered office; for medicinal products included in specific therapeutic programmes and for foods for special medical purposes this shall mean the abbreviation of the country of manufacturer's/importer's registered office. A common implemental index is available for the DRZ and ZEM DRZ fields.
11	O		C	16	MA number	Marketing authorisation number, which identifies a group of presentations of a medicinal product for which the marketing authorisation has been issued.
12	O		C	11	Parallel import ID	The identification number of parallel import, which is associated with the respective reference product as per MA number; usually in the following format: PI/xxx/tyty
13	O		C	3	MA type	Marketing authorisation (type of marketing authorisation – national, MRP, DCP, via centralised procedure, adopted MA, parallel import).
14	M		C	2	MA status	Status of the marketing authorisation, the basic values being as follows: R – Authorised medicinal product B – Following an implemented variation thereto, a product may be marketed for the period of 6 months and used until its expiry date, not exceeding the MA expiry date Q – The product could be marketed for the period of 6 months following an implemented code conversion and may be used until its expiry date not exceeding the MA expiry date F – Specific therapeutic programme authorised by the Ministry of Health of the Czech Republic upon SÚKL's recommendation P – Foods for special medical purposes STAVREG status value implemental index is available for the S_REG field.
15	M		N	13,2	Max. ex-factory price	Maximum ex-factory price of the medicinal product/food for special medical purposes

16	M		C	1	Max. ex-factory price legal basis	Legal basis for setting the MP/FSMP ex-factory price; applicable values: S – Established or amended via administrative procedure under Act No 48/1997 Coll., as amended as of January 1, 2008 P – Temporary <i>ex lege</i> price decrease, i.e. a temporary price decrease set forth by the law M – Price set by the Czech Finance Ministry under Act No 265/1991 Coll. and Act No 526/1990 Coll., as amended before December 31, 2007 N – The stated price is the <i>ex lege</i> established or amended price at which the applicant may market the MP or the FSMP, if no decision on their applications has been taken within the timelines set out by Act No 48/1997 Coll., as amended. This price equals the price stated in the application for maximum price determination or change thereof. This price shall be effective until an effective decision is issued in the matter.
17	O		C	20	Grounds for max. ex-factory price	Contains the file no. of administrative procedure before SÚKL
18	O		C	7	Full ATC	Anatomical therapeutic chemical group. An ATC implemental index is available for the ATC field.
19	O		D	8	MA effective date	Effective date of the marketing authorisation
20	O		D	8	MA expiry date	Expiry date of the marketing authorisation, unless unlimited validity has been granted pursuant to Section 34 of the Act on Pharmaceuticals.
21	O		C	1	Unlimited MA validity	Field to be completed (X) where unlimited validity of the marketing authorisation applies.
22	O		D	8	Placement on market	Date of initial placement of supplies of the medicinal product on the market or reinstatement thereof, to be reported by the MA holder in compliance with Section 33 of the Act on Pharmaceuticals.
23	O		D	8	Supply termination	Date of termination or discontinuation of supplies of the medicinal product onto the market, to be reported by the MA holder in compliance with Section 33 of the Act on Pharmaceuticals
24	O		C	4	Amount of active substance in DDD	Defined daily dose - the amount of active substance – information as per WHO
25	O		C	2	Unit of active substance in DDD	Defined daily dose – unit – information as per WHO
26	O		N	11,4	DDD count in MP pack	The number of defined daily doses in a pack - where DDD has been established by WHO
27	O		D	8	MCV Validity	Date of change to the determined maximum ex-factory price
28	O		C	1		Reserve field 1
29	O		C	15		Reserve field 6
30	O		C	10		Reserve field 7

Code page: 1250 WIN CZ

Field separator: “|”

The “M/O” column identifies mandatory and optional fields of the List.

The “Type” column identifies the format of the fields as follows: “C” – character attribute

“N” – numeric attribute

“D” – date in the “ddmmyyyy” format

The “Size” column identifies the scope of the fields. The format of numerical fields is identified as “x,y” (“x” numbers, incl. the decimal point, of which “y” decimal numbers).